For instance, in NSCLC, KRAS G12D mutations are associated with low or never smoking status, lower PD-L1 expression, and worse outcomes to PD-(L)1 blockade (73), which could suggest potential variations in response among different mutant-specific inhibitors. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.